BACK TO ISCBH HOME

Awards and Grants

GET IN TOUCH

Awards

A number of awards are offered during the ICCBH conference to eligible authors, including:

ICCBH New Investigator Awards

These awards are made by the Programme Organising Committee based on scores achieved during the abstract review process.

New Investigator Award eligibility form for download – ICCBH awards – confirmation of eligibility

In order to be considered for an award you:

  1. Must be first and presenting author.
  2. Must be in training or within 5 years of attaining PhD or MD or equivalent.

If you do not fit the above criteria, however, consider that you are eligible due to extenuating circumstances, please complete the box on the confirmation of eligibility form explaining why you feel you should be considered.

Best Oral and Best Poster Awards

These awards are chosen at the conference by the delegates (posters) and by a judging panel (orals). All accepted abstracts are considered for these awards.

The Charles Slemenda Award

The Charles Slemenda Award, established in 1999, is awarded biennially at the ICCBH conference in recognition of outstanding contributions to children’s bone research.  The recipient is selected by the ICCBH Steering Group and POC.

Previous recipients of the Charles Slemenda Award:

  • 1999  Francis Glorieux
  • 2002  John Pettifor
  • 2005  Jean-Philippe Bonjour
  • 2007  Ailsa Goulding
  • 2009  Michael Whyte
  • 2013  Maria Luisa Bianchi
  • 2015  Zulf Mughal
  • 2017  Frank Rauch
  • 2019  Nick Bishop
  • 2022 Outi Makitie
  • 2024 Thomas Carpenter

The Maria Luisa Bianchi Award

The Maria Luisa Bianchi Award was established in 2021 by ICCBH to honour the memory of Professor Maria-Luisa Bianchi for her role in in establishing and developing ICCBH and for her significant impact on the field of paediatric bone disease through her research and clinical work. The Award reflects on her commitment to the development of the field.

The goal of the award is to recognise the work of female researchers towards the beginning of their careers who have already made a significant contribution to the field of paediatric bone health and who are based in low- and middle-income countries.

The award will be made on the occasion of the International Conference on Children’s Bone Health, currently on a biennial basis and the recipient is selected by the ICCBH Steering Group.

Previous recipients of the Maria Luisa Bianchi Award:

  • 2024  Sare Betül Kaygusuz

The deadline for nominations for this award is 31 January 2026 (23:59 GMT) – more information about the eligibility and nomination process can be found HERE

Grants

ICCBH Travel Grants

New for ICCBH 2026 we have a programme of travel grants available aimed at supporting our early career colleagues to attend ICCBH 2026. To be eligible for a travel grant you must:

  • B a trainee, or early career/junior faculty
  • Be a member of the ISCBH, (join here)
  • Have submitted an abstract

The following grants are available for each region:

  • Travelling from Europe – up to €1,000
  • Travelling from N. America – up to €500
  • Travelling from Latin America – up to €1,000
  • Travelling from Asia – up to €1,500
  • Travelling from Africa – up to €1,500

The grant will cover transport, hotels and subsistence and can be claimed following attendance at the conference. We will require a form with your bank details and receipts and also a report showing how your attendance at the conference benefited you.

To apply email us and show that you meet the above criteria (please include the title and reference number of your abstract) by Tuesday 31st March 2026

If you have any questions, please contact us

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE
BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE